Latest Conference Articles

João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means for gene therapy eligibility

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now.

At WIO 2026, Durga Borkar, MD, discussed DAVIO2 trial results for EYP-1901 in wet AMD.

Matias Iglicki, MD, PhD, on patient selection, technical pitfalls and why symmetry decides outcomes in flanged vs sutured fixation

Amy Zhang, MD, on why self-care alone won't fix physician burnout and what health systems need to address instead.

The Aug. 20-23 meeting in Monterey, California, offers CME across subspecialties alongside sessions on mentorship, career longevity, and research.

Amy Zhang, MD, on the ergonomic habits and equipment changes that protect ophthalmic surgeons' careers long-term.

25.5% of patients labeled with MacTel2 didn't meet diagnostic criteria, most often due to cystic OCT changes and telangiectatic vessels mistaken for the disease.

Stuart Therapeutics presented preclinical data at OIS Retina 2026 on a non-gene-specific collagen mimetic peptide that preserved retinal thickness and visual function in 2 mouse models of inherited retinal disease.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of patients with wet AMD by year 1, worsening vision.

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

A University of Chicago-led ASRS 2026 poster explores how large language and vision-language models could help retina specialists manage imaging, records, and clinical trial matching—without replacing physician judgment.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.

Louie Cai, MD, discusses why manual prescreening is so labor-intensive, how the study was designed, and what broader adoption of AI-assisted screening could mean for clinician time, patient satisfaction, and the pace of drug development.

Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central serous chorioretinopathy (CSCR)

Carl C. Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, with strong safety through 4 years of follow-up.

In a first-in-human Phase 1 trial, a single TH103 injection improved vision and reduced fluid in treatment-naive wet AMD, with roughly a third of patients needing no retreatment through 6 months.

5-year OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained aflibercept expression and no new safety signals, in a high-need population with nAMD.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.

A wider partial-total ellipsoid zone gap on OCT predicted faster total EZ loss and geographic atrophy in intermediate AMD—pointing to a biomarker for trial enrichment.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year, and treatment gaps are linked to worse long-term vision.

3-year REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.

AI-driven OCT analysis shows faricimab reduces diabetic macular edema fluid and thickness more than aflibercept, suggesting eccentric subfields may guide treat-and-extend dosing.